NASDAQ$TECX

Tectonic Therapeutic Inc · Q4 2024 earnings

Q4 2024 earnings · · Investor relations

Briefing

Tectonic Therapeutic reported Q4 2024, net loss of $12.4M.

For Q4 2024, Tectonic Therapeutic reported a net loss of $12.4M. Management discussed operating trends, liquidity, and outlook in the linked filing.

  • Net loss $12.4M.
  • Tectonic Therapeutic highlights segment execution and capital priorities.
  • Tectonic Therapeutic highlights segment execution and capital priorities.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.84

Previous: -$0.20-320.0%
Net Loss Per Share

-$0.84

Previous: -$5.01+83.2%
R&D Expenses

$9.16K

Previous: $7.08K+29.3%
G&A Expenses

$4.83K

Previous: $2.29K+111.0%
Total Operating Expenses

$14K

Previous: $9.37K+49.3%
Interest Income

$1.74K

Previous: $132.00+1214.4%
Interest Expense

-$23.00

Previous: -$34.00+32.4%
Other Expense

-$96.00

Previous: $405.00-123.7%
Total Other Income (Expense), Net

$1.62K

Previous: $1.5K+7.5%
Comprehensive Loss

-$12.3K

Previous: -$7.88K-56.0%
Weighted-Average Shares Outstanding

14.8M

Previous: 1.6M+842.1%
Working Capital

$135K

Previous: -$10K+1451.9%
Net Income

-$12.4M

Previous: -$8.79M-41.1%
Operating Income

-$14K

Previous: -$9.63M+99.9%

Revenue & EPS history

Tectonic · Revenue · Quarterly

$0

Q4 2024

Forward guidance

The filing discusses Tectonic Therapeutic's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.

Tailwinds

  • Clinical milestones and cash runway extend development timelines.
  • Tectonic Therapeutic discussed operating priorities and capital allocation for upcoming periods.
  • Liquidity and balance-sheet capacity support ongoing operations.

Headwinds

  • GAAP profitability remained under pressure in Q4 2024.
  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect year-over-year comparability.
  • R&D spend and trial outcomes drive near-term losses.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.4%

Avg return

Earnings day

-1.0%

Avg return

5 days after

+2.9%

Avg return

30 days after

41%

7 / 17 earnings

Positive

+11.1%

Q4 2021

Best reaction

-20.3%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.4%+14.5%+22.6%
Q3 2025+1.5%-0.7%+4.9%
Q1 2025-0.9%+3.5%-13.4%
Q4 2024+1.0%-11.8%+11.0%
Q3 2024-2.0%+6.5%+14.8%
Q1 2024+0.0%-0.8%-7.0%
Q4 2023+0.8%-2.3%-1.6%
Q3 2023-9.9%-13.2%-7.2%
Q2 2023+0.6%-1.9%+4.5%
Q1 2023-4.5%-4.5%+82.1%
Q4 2022-20.3%-14.6%-23.6%
Q3 2022-1.5%+12.1%+19.7%
Q2 2022+5.0%+5.9%-12.9%
Q1 2022-7.3%-1.2%+30.5%
Q4 2021+11.1%+12.5%-20.8%
Q3 2021-1.0%-3.8%-40.7%
Q2 2021+6.5%-17.0%-13.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro